【摘 要】目的：观察第三代铂类抗癌药物洛铂通过支气管动脉介入给药联合口服足叶乙甙治疗晚期小细胞肺癌的毒副反应及护理。方法：收集我科2010年11月～2012年1月20例经病理组织学和/或细胞学检查确诊的小细胞肺癌患者，均为初治病例，采用洛铂30mg/㎡通过支气管动脉介入灌注第1天，足叶乙甙第1天～第5天口服，100mg/天，每3～4周重复。结果：主要毒副反应为可逆性的骨髓抑制。结论：支气管动脉介入灌注洛铂联合足叶乙甙治疗晚期小细胞肺癌疗效佳，毒副反应轻，易于耐受，护理方便。

    【关键词】肺肿瘤；小细胞肺癌；洛铂；足叶乙甙；支气管动脉灌注；护理

    【中图分类号】R 734.2；R 473.73 【文献标识码】A 【文章编号】1004- 7484(2012)05- 0389- 01

    Bronchial Arterial Interventional Perfusion Lobaplatin Ioint Etoposide Treatment of Advanced Small Cell lung Cancer Care Experience

    Fei ri J ie, lian Guiqiu, Liu Hongli

    【Abstract】Objective: To observe the third-generation platinum anticancer drugs lobaplatin involved through the bronchial artery administration of combined oral enough Vp treatment of advanced small cell lung toxicity and care.: Collection department from November 2010 to 2012, January 20 cases with histologically and / or cytology diagnosis of small cell lung cancer patients were previously untreated cases, lobaplatin 30mg / m perfusion through the bronchial artery intervention on day 1, etoposide on day 1 ～ 5 days of oral, 100mg / day, repeated every 3 to 4 weeks. The results：of the main side effects were reversible bone marrow suppression. Conclusion：bronchial artery intervention to perfusion lobaplatin joint foot and VP treatment of advanced small cell lung cancer clinical outcome, toxicity is light, easy tolerance, convenient care. ......